<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722863</url>
  </required_header>
  <id_info>
    <org_study_id>156-KOA-1201n</org_study_id>
    <nct_id>NCT02722863</nct_id>
  </id_info>
  <brief_title>Samsca Post Marketing Surveillance Study</brief_title>
  <acronym>Samsca PMS</acronym>
  <official_title>Post Marketing Surveillance Study of Safety and Efficacy of Samsca® Tablets Under the &quot;New Drug Re-Examination&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Post-Marketing Surveillance will be conducted in accordance with the local regulation of
      New Drug Re-examination. The surveillance will be conducted for 6 years of the re-examination
      period (01Sep2011~31Aug2017). Each subject will be observed at least for 4 days during the
      surveillance period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted as a prospective, single-arm, multicenter study. Findings on
      examination, diagnosis, opinions and observations implemented as per general medical practice
      during the observational period will be documented in the case report forms by the
      investigators or responsible staffs at the institution since the surveillance is an
      observational study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The numbers of subjects presenting at least one adverse event/adverse drug reaction, at least one serious adverse event/adverse drug reaction, or at least one unexpected adverse event/adverse drug reaction.</measure>
    <time_frame>Follow-up at least 4 days after first Samsca® dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects presenting at least one adverse event/adverse drug</measure>
    <time_frame>Follow-up at least 4 days after first Samsca® dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence rate of subjects presenting at least one adverse event/adverse drug</measure>
    <time_frame>Follow-up at least 4 days after first Samsca® dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who discontinued Samsca® (inc.due to an adverse event)</measure>
    <time_frame>Follow-up at least 4 days after first Samsca® dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who discontinued Samsca® (inc.due to an adverse event)</measure>
    <time_frame>Follow-up at least 4 days after first Samsca® dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the serum sodium level at the first visit and Day 4 after the first visit</measure>
    <time_frame>Follow-up at least 4 days after first Samsca® dose</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hypervolemic and Euvolemic Hyponatremia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The treatment of clinically significant hypervolemic and euvolemic hyponatremia [serum
        sodium &lt; 125 mEq/L or hyponatremia that is symptomatic and has resisted correction with
        fluid restriction], including patients with heart failure, cirrhosis, Syndrome of
        Inappropriate Antidiuretic Hormone (SIADH) and etc.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following inclusion criteria to be eligible for
             enrollment into the study :

               1. Patients who have hyponatremia in euvolemic or hypervolemic states, defined as
                  serum sodium level &lt; 125 mEq/L or hyponatremia that is symptomatic and has
                  resisted correction with fluid restriction

               2. Patients who are prescribed Samsca® treatment as per investigator's medical
                  judgment

               3. Patients who gave written authorization to use their personal and health data

               4. Patients starting Samsca® treatment after agreement is in place Investigators
                  will refer to the product market authorization (label) for inclusion criteria.

        Exclusion Criteria:

          -  Subjects presenting with any of the following will not be included in the study:

               1. Patients who have been treated with Samsca®

               2. Patients with known or suspected hypersensitivity to tolvaptan or to any
                  ingredient of the drug

               3. Patients requiring urgent intervention to raise serum sodium acutely.

               4. Inability of the patient to sense or appropriately respond to thirst.

               5. Hypovolemic hyponatremia

               6. Concomitant use of strong CYP3A inhibitors

               7. Anuric patients

               8. Volume depletion patients

               9. Hypernatremia patients

              10. Women who are pregnant or possibly pregnant and lactation

              11. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
                  deficiency or glucose-galactose malabsorption Investigators will refer to the
                  product market authorization (label) for exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bong Seng Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47889</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Hwan Lee</last_name>
      <email>sooji523@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Sung Ahn</last_name>
      <email>ksahn@cu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Wook Lee</last_name>
      <email>kwlee@cnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Ho Hwang</last_name>
      <email>dennyjinho@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

